Allogeneic hematopoietic stem cell transplantation (HSCT) is an established treatment option for high-risk hematological malignancies, and may also be offered to patients with solid malignancies refractory to conventional therapies. In case of patients' relapse, refractory tumor cells may then be targeted by cellular therapy-based combination strategies. Here, we investigated the potential of small molecule IAP (SMAC mimetic) BV6 in increasing cytokine-induced killer (CIK) cell-mediated cytotoxicity against different tumor targets. Four-hour pre-incubation with 2.5 µMol BV6 moderately enhanced CIK cell-mediated lysis of hematological (H9, THP-1, and Tanoue) and solid malignancies (RH1, RH30, and TE671). However, BV6 also increased apoptosis of non-malignant cells like peripheral blood mononuclear cells and most notably had an inhibitory effect on immune cells potentially limiting their cytotoxic potential. Hence, cytotoxicity increased in a dose-dependent manner when BV6 was removed before CIK cells were added to tumor targets. However, cytotoxic potential was not further increasable by extending BV6 pre-incubation period of target cells from 4 to 12 h. Molecular studies revealed that BV6 sensitization of target cells involved activation of caspases. Here, we provide evidence that SMAC mimetic may sensitize targets cells for CIK cell-induced cell death. However, BV6 also increased apoptosis of non-malignant cells like CIK cells and peripheral mononuclear cells. These findings may therefore be important for cell-and small molecule IAP-based combination therapies of resistant cancers after allogeneic HSCT.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) is an established strategy for treatment of high-risk hematological malignancies, and is also offered to patients with solid malignancies refractory to conventional therapies (1) . But still, due to tumor cell resistance, the therapeutic success of this approach is limited by patients' relapse. Hence, new therapeutic strategies are needed, which may combine cellular therapies and small molecule drugs for retargeting of resistant tumor cells. Immune cell-based combination strategies may not only include chimeric antigen receptor (CAR) bearing T cells (2, 3) , T cell receptor (TCR) transduced T cells (4, 5) , or specific cytotoxic T lymphocyte (CTL) clones (6, 7) , but may also include non-specific immune cell approaches using cytokine-induced killer (CIK) cells.
CIK cells are activated and expanded in vitro from peripheral blood mononuclear cells (PMNCs) by timed addition of cytokines. Expanded CIK cells represent a heterogeneous population of CD3 + CD56 − T cells and CD3 − CD56 + natural killer (NK) cells. T cells in part share both CD3 + T cell and CD56 + NK cell phenotype (CD3 + CD56 + T-NK cells). CIK cells are able to eradicate a variety of hematological and solid malignancies in a non-major histocompatibility complex (MHC)-restricted manner without possessing significant alloreactive potential (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . Therefore, the application of CIK cells has evolved from experimental observations into early clinical allogeneic HSCT studies. These trials included transplanted patients who had relapsed from hematological malignancies. Most of these patients showed transient clinical responses after CIK cell infusions (18) (19) (20) . Anti-leukemic activity of CIK cells, without long lasting efficacy, may suggest limited lifespan of infused CIK cells or resistance mechanisms developed by target cells.
Inhibitors of apoptosis (IAP) proteins are associated with chemo-resistance, disease progression, and poor prognosis in different cancers (21, 22) . Therefore, IAPs may be interesting for retargeting tumor cells toward unspecific CIK cell-based killing by using a combination of CIK cells and small molecule IAP (SMAC mimetics/IAP antagonists) (23) .
The divergent structures of SMAC mimetics originate from the conserved AVPI tetrapeptide N-terminal sequence of SMAC/DIABLO (direct inhibitor of apoptosis-binding protein www.frontiersin.org with low isoelectric point/direct IAP-binding protein with low pI) that binds to the BIR domains of IAP proteins with high affinities to promote cell death and inhibit tumor growth in in vivo models. In response to apoptotic stimuli, following the death trigger, mitochondria may become selectively permeabilized, SMAC along with pro-apoptotic proteins such as cytochrome c are released from the intermembrane space of mitochondria into the cytoplasm (24) . SMAC is a dimer and interacts with its four N-terminal amino acid residues (AVPI) with XIAP to abrogate XIAP-mediated inhibition of caspases-3 and -9 leading to dissociation of bound caspases from XIAP (25) .
One important contribution of IAP proteins to cell survival and tumorigenesis is the ability of several IAP proteins to regulate alternative nuclear factor (NFκB) signaling. cIAP1 and cIAP2 are involved in degradation of the MAP3 kinase, NFB inducing kinase (NIK) in the NFκB pathway (23, (26) (27) (28) (29) , and contribute to activation of the classical NFκB pathway by tumor necrosis factor (TNF) stimulation (30) (31) (32) . Besides preventing the XIAP interaction with caspases, SMAC mimetics induce activation of the NFκB pathway by binding to cIAP1 and cIAP2 and stimulating the E3 ubiquitin-ligase activity of the cIAP proteins (33) .
So far, several small molecules that mimic the IAP binding of motif of SMAC and pharmacologically inhibit IAP protein function were designed and described (34) . Beside BV6 (23), birinapant (TL32711) a biindole-based bivalent SMAC mimetic recently showed promising synergistic cytotoxicity of several widely used anti-cancer agents in pre-clinical analyses (35, 36) .
This study was performed to assess the role of bivalent SMAC mimetic BV6 in increasing susceptibility of target cells toward CIK cell-mediated killing in cell line models. Our findings may be important for cell-based combination strategies in the treatment of resistant tumor cells.
MATERIALS AND METHODS

CELL LINES
T cell lymphoma cell line H9, subtype M4 acute myeloid leukemia cell line THP-1, precursor-B acute lymphoblastic leukemia cell line Tanoue, Ewing sarcoma cell line RH1, alveolar rhabdomyosarcoma cell line RH30, and embryonal rhabdomyosarcoma cell line TE671 were obtained and cultured as previously described (13, 17) .
CIK CELLS
CIK cells were generated as previously described from PMNCs of healthy donors in accordance with the institutional review board approval and after written informed consent (Geschäfts-Nr.: 298/07) (17) . In brief, after 10 days of in vitro stimulation with interferon (IFN)-γ, anti-CD3 antibody, and interleukin (IL)-2 and IL-15, CIK cells were harvested and used in experiments.
EUROPIUM RELEASE ASSAY
Europium release assay was used to assess lytic activity of CIK cells with or without pre-treatment of target cells with SMAC mimetic BV6. In brief, target cells used (H9, THP-1, Tanoue, RH1, RH30, TE671, and PMNCs) were labeled with BATDA (DELFIA ® BATDA Labeling Reagent, PerkinElmer, Waltham, MA, USA). Labeled target cells were pre-incubated with 2.5 µMol BV6 for 4 h or remained without BV6 treatment. To further analyze dosage and timing of target cell sensitization by BV6, selected hematological and solid malignancies (THP-1 and RH30) were labeled with BATDA, sensitized with 2.5 and 10 µMol BV6 for 4 h and were washed to remove BV6 before being used in experiments. In addition, more resistant targets cell lines (RH30 and TE671) were pre-incubated with 2.5 and 10 µMol BV6 for 12 h and were washed before being labeled and introduced to CIK cells in experiments.
Next, these different pre-treated target cells were cultured on U-bottomed-96-well culture plates (NUNC, Langenselbold, Germany). CIK cells were added at an effector to target cell (E:T) ratio of 20:1. After another period of 3 h, 20 µL of supernatant was collected out of each well and introduced to 200 µL europium solution (Europium, Perkin Elmer, Turku, Finland). Fluorescence data were recorded using a time resolved fluorometer (1420-018 Victor, Perkin Elmer, Waltham, MA, USA). The measured signal correlated with the amount of destroyed cells. Maximum release of BATDA was obtained by incubating target cells with 4% triton (Triton X-100, Sigma-Aldrich, Munich, Germany). Target cells without effector cells were used as negative control (spontaneous release). The percentage of specific cytolysis was calculated as experimental release minus spontaneous release divided through maximum release minus spontaneous release of target cells multiplied by 100.
FLOW CYTOMETRY
Malignant and non-malignant target cells THP-1 and PMNCs were incubated for 4 h with 2.5 and/or 10 µMol BV6 followed by co-incubation with CIK cells at an E:T ratio of 5:1 for 3 h. BV6 pre-treated target cells and CIK cells alone served as controls. Cell suspensions were then stained using FITC Annexin V Apoptosis Detection Kit with 7AAD (Bio Legend, San Diego, CA, USA) according to the manufacturer's instructions. Antihuman CD3-PC7, CD25-PE, and CD33-PE (Beckman Coulter, Krefeld, Germany) as well as forward scatter were used to differentiate between CD33 + THP-1, CD3 ± CD25 + CD33 ± CIK cells and CD3 ± CD25 ± PMNCs by flow cytometry (FC500 Beckman Coulter). Percentages of Annexin V-positive apoptotic and 7AAD-positive necrotic cells are shown. Cytotoxicity results included Annexin V-positive and/or 7AAD-positive cells.
IMMUNOFLUORESCENT STAINING AND CONFOCAL MICROSCOPY
Target cells were grown together with CIK cells in chamber slides. Cells were fixed with 4% paraformaldehyde, permeabilized with 0.2% triton X-100 for 30 min, and intracellularly stained with caspase-3 phycoerythrin (PE)-labeled for 30 min at room temperature. To distinguish between CIK and RH30 cells, CIK cells were stained with fluorescein isothiocyanate (FITC)-labeled anti-CD45 antibody for 30 min at room temperature. Images were obtained using a confocal microscope. Images were computer processed by Zeiss LSM Image Browser.
WESTERN BLOT ANALYSIS
BV6-mediated killing mechanism was analyzed in co-cultures of tumor and CIK cells. TE671 (TE) cells that were efficiently killed by combination therapy and grown in adherent cultures allowing a segregation of effector and target cells by several washing steps were used for analyses. Analyzed samples included TE and CIK cells alone, TE and CIK cells pre-incubated with 2.5 µMol BV6 for 4 h, TE cells co-cultured with CIK cells at an E:T ratio of 20:1 for 3 h, and TE cells pre-incubated with 2.5 µMol BV6 for 4 h followed by co-culture with CIK cells at an E:T ratio of 20:1 for 3 h. Co-cultures of TE and CIK cells were washed for the removal of CIK cells before TE cells were analyzed by western blot analysis. Western blot analysis was performed as described previously using the following antibodies: mouse anti-caspase-8 (1:1000; Alexis Biochemicals, Gruenberg, Germany), rabbit anti-Bid, rabbit anti-caspase-3, and rabbit anti-caspase-9 (1:1000; Cell Signaling, Beverly, MA, USA). Mouse anti-β-actin (1:10000; Sigma) was used as loading control (37) . Goat anti-mouse IgG and goat anti-rabbit IgG conjugated to horseradish peroxidase (1:5000; Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used as secondary antibodies. Enhanced chemiluminescence was used for detection (Amersham Bioscience, Freiburg, Germany).
INHIBITION OF CASPASE ACTIVATION BY zVAD
BV6 and CIK cell-mediated cytotoxicity mechanism was analyzed by europium release assay against TE671 cells after 4 h pre-incubation with 2.5 µMol BV6. To analyze whether BV6 and CIK cell treatment induces apoptosis by caspase activation, 50 mM zVAD was added. zVAD is a cell-permeant pan caspase inhibitor that irreversibly binds to the catalytic site of caspase proteases and inhibits induction of apoptosis by the caspase cascade.
STATISTICAL ANALYSIS
Statistical significance was assessed by two-sided Student's t-test using PRISM 6. Results from independent experiments are shown as mean with standard error of the mean (SEM).
RESULTS
CYTOTOXICITY OF CIK CELLS AGAINST TUMOR CELLS IN THE PRESENCE OF BV6
Europium release assay was performed to evaluate the effect of BV6 on CIK cell-mediated killing of tumor targets. Thereafter, CIK cells were added for 3 h at an E:T ratio of 20:1. Europium release measurements confirmed CIK cell-mediated target cell killing in the presence of BV6 (Figure 1) . Combination treatment of CIK cells and BV6 was referred to standard control without BV6 and resulted in moderately increased lysis of targets cells in the presence of 2.5 µMol BV6 (Figure 1: H9, (A) ; THP-1, (B); Tanoue, (C); RH1, (D); RH30, (E); TE671, (F)).
CYTOTOXICITY OF CIK CELLS AGAINST NON-MALIGNANT PMNCs IN THE PRESENCE OF BV6
To mimic cytotoxic potential of combination therapy of CIK cells and BV6 against non-malignant cells like PMNCs, the latter were freshly isolated by Ficoll ® density centrifugation, labeled, treated in part with BV6, and used for analysis in europium release assay. Combination treatment significantly increased CIK cell-mediated killing of PMNCs (mean ± SEM: w/o BV6, 16.0 ± 0.4%; 2.5 µMol BV6, 22.0 ± 0.4%, p < 0.0001, (n = 4); Figure 2A ).
This analysis was also performed by flow cytometry as cytolysis of non-malignant cells may limit applicability of combination therapy. Therefore, PMNCs treated with 2.5 µMol BV6 and untreated PMNCs were incubated with CIK cells at an E:T ratio of 5:1. For analysis of apoptotic and necrotic cells, cell suspensions were stained with Annexin V FITC and 7AAD, respectively. PMNCs were identified by forward scatter and CD25-expression and excluding CD25-expressing larger CIK cells. Compared to untreated controls (apoptotic cells, 7.3%; necrotic cells, 1.8%), PMNCs were not affected by BV6 treatment alone (apoptotic cells, 6.5%; necrotic cells, 1.8%), but were impaired by CIK cell treatment (apoptotic cells, 11.4%; necrotic cells, 3.8%) and furthermore by combination therapy (apoptotic cells, 16.8%; necrotic cells, 3.2%) shown by one representative example ( Figure 2B) . Flow cytometry results of independent experiments showed that combination treatment increased CIK cell cytotoxicity toward PMNCs, but differences were not significant (mean ± SEM of Annexin V-and/or 7AAD-positive PMNCs: w/o BV6, 12.1 ± 3.2%; 2.5 µMol BV6, 27.5 ± 7.5%, (n = 3); Figure 2C ).
CIK CELL CYTOTOXICITY AGAINST TUMOR CELLS AFTER PRE-TREATMENT AND REMOVAL OF BV6
To analyze whether target cell sensitization by BV6 was increasable, selected hematological (THP-1, Figure 3A ) and solid malignancies (RH30, Figure 3B ) were pre-treated with increasing concentrations of BV6 for 4 h and were washed before being incubated with CIK cells in the europium release assay. Sequential use of BV6 and CIK cells such that the SMAC mimetic effect is restricted to the targets, increased CIK cell-mediated killing of RH30 and THP-1 cells in a dose-dependent manner (THP-1, mean ± SEM: w/o BV6, 64.7 ± 3.7%; 2.5 µMol BV6, 71.3 ± 2.7%; 10 µMol BV6, 79.3 ± 4.7%, n.s. (n = 3), Figure 3A ; RH30, w/o BV6, 45.0 ± 2.1%; 2.5 µMol BV6, 52.3 ± 1.5%, p = 0.0446; 10 µMol BV6, 62.3 ± 2.8%, p = 0.0080, (n = 3), Figure 3B ). Hereby, maximum cell lysis was achieved after target cell pre-treatment with 10 µMol BV6.
In addition, relatively resistant target cell lines like RH30 ( Figure 3C ) and TE671 cells ( Figure 3D) were incubated with BV6 for 12 h, washed and introduced to CIK cells in the europium release assay. Extended pre-incubation period also resulted in significantly increased CIK cell-mediated killing of RH30 and TE671 cells, but increase of cytotoxicity was not dosedependent and was not enhanced compared to 4 h target cell pre-incubation period (RH30, w/o BV6, 28.0 ± 3.1%; 2.5 µMol BV6, 40.5 ± 2.5%, p = 0.0188; 10 µMol BV6, 36.3 ± 1.5%; (n = 4), Figure 3C ; TE671, w/o BV6, 21.7 ± 8.5%; 2.5 µMol BV6, 55.0 ± 3.1%, p = 0.0087; 10 µMol BV6, 57.0 ± 5.5%, p = 0.0248; (n = 3), Figure 3D ).
CIK CELL CYTOTOXICITY AGAINST TUMOR CELLS IN THE PRESENCE OF DOSE ESCALATED BV6
Dose escalating effects of BV6 regarding tumor cell sensitization toward CIK cell-mediated killing was also analyzed by flow cytometry. Therefore, THP-1 cells with BV6 pre-treatment were incubated with CIK cells at an E:T ratio of 5:1. THP-1 cells alone and THP-1 cells with BV6 or CIK cell treatment alone Frontiers in Pediatrics | Pediatric Oncology Figure 4A ) demonstrated that cytotoxic effects of BV6 (THP-1, mean ± SEM: w/o BV6, 7.4 ± 0.6%; 2.5 µMol BV6, 15.0 ± 0.6%; 10 µMol BV6, 25.5 ± 2.8%) and CIK cells (THP-1, mean ± SEM: 20.3 ± 4.6%) alone were moderate, but significantly increased in a dose-dependent manner after combining BV6 and CIK cell treatment (THP-1, mean ± SEM: 2.5 µMol BV6 + CIK cells, 27.2 ± 2.4%; 10 µMol BV6 + CIK cells, 42.4 ± 3.3%, Figure 4B ).
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INFLUENCES OF BV6 AND TARGET CELLS ON CIK CELLS
To analyze whether BV6 also influences CIK cells and thereby their cytotoxic potential, CIK cells were analyzed after fourhour incubation with 2.5 and 10 µMol BV6. Results measured by flow cytometry showed that CIK cells were affected by BV6 in a dose-dependent manner (w/o BV6, apoptotic cells, 5.4%; necrotic cells, 1.9%; 2.5 µMol BV6, apoptotic cells, 12.0%; necrotic cells, 1.2%; 10 µMol BV6, apoptotic cells, 17.8%; necrotic cells, 3.8%) ( Figure 5A ). Next we analyzed whether killing of target cells induced apoptosis in CIK cells. To this end, CIK cells were co-incubation with alveolar rhabdomyosarcoma cell line RH30. CIK cells were stained with FITC-labeled anti-CD45 antibody. Induction of apoptosis was shown by expression of caspase-3 stained with PE and visualized by fluorescence microscope analysis. As a sign of ongoing apoptosis, CIK cells being in contact with tumor cells and tumor cells both expressed caspase-3 ( Figure 5B) . Cytotoxicity of BV6 on CIK cells alone or in the presence of malignant (THP-1) and non-malignant cells (PMNC) was analyzed by flow cytometry. Cytotoxicity results showed that cytolysis of CIK cells increased with killing of malignant targets and escalating doses of BV6 ( Figure 5C ).
CIK CELL-MEDIATED KILLING OF TUMOR CELLS BY BV6 INVOLVES THE CASPASE CASCADE
Western blot analysis was used to identify underlying killing mechanism of combination therapy ( Figure 6A . This was evident from the increased cleavage of caspase-8, -3, and -9 into active cleavage fragments in the presence of BV6 and CIK cells, that is, caspase-8 into active p43 and p41 fragments, caspase-3 into active p17 and p12 fragments and caspase-9 into active p37 and p35 fragments. Moreover, Bid was predominately cleaved into tBid, the activated form of Bid, upon BV6 and CIK cell treatment ( Figure 6A) . Addition of zVAD a caspase inhibitor reduced killing of TE671 cells by 50% (Figure 6B) . Collectively, these data demonstrate that BV6 increases susceptibility of TE671 cells to CIK cell-mediated cytolysis by triggering caspases activation and apoptosis.
DISCUSSION
Resistance of tumor cells still remains an unsolved problem in high-risk cancers after allogeneic HSCT. Tumor cells may even survive additional cell therapeutic strategies for augmentation of allogeneic effects post-transplant. Sequential therapy with apoptosis-sensitizing agents was previously shown for chemotherapy, radiation, HDAC inhibitors, JAK/STAT inhibitors, proteasome inhibitors, or tyrosine kinase inhibitors, but not CIK cells (38) (39) (40) (41) (42) (43) (44) (45) (46) . Improved therapeutic options may therefore include non-MHC restricted CIK cell infusions combined with targeted cancer therapies. Due to the fact that IAP expression or function is deregulated in many refractory cancers, several IAP-targeting agents including SMAC mimetics are currently being tested in vitro and in vivo in early clinical trials (21) (22) (23) (24) (25) (26) (47) (48) (49) (50) (51) . It was found that SMAC mimetics allow sensitization of tumor cells for apoptosis induction by releasing caspases from the inhibitory interaction with IAP proteins, particular XIAP (49, 52) and that SMAC mimetics have complex effects on NFκB and TNF signaling (23, 26, 29-31, 51, 53, 54) . But, due to the importance of NFκB in immune cells, SMAC mimetics might also modulate immune cell functions and therefore influence cell-based combination therapies, e.g., by modulating NFκB signaling in immune cells. In this study, we analyzed the cytotoxic effects of CIK cells against tumor cells in the presence of the bivalent SMAC mimetic BV6.
Our results showed that BV6 sensitization of hematological and solid malignancies, i.e., H9, THP-1, Tanoue, RH1, RH30, and TE671 cell lines toward CIK cell-mediated killing was limited. To analyze and further increase the impact of BV6 treatment on target cell sensitization, target cells were incubated with escalating doses of BV6 and incubation period was extended from 4 to 12 h before BV6 was removed and CIK cells were added for cytotoxicity analysis. In fact, when used sequentially increased dosage of BV6 correlated with the greater BV6 sensitivity of target cell lines toward CIK cell-mediated killing.
However, cytotoxicity was not further increasable by extending BV6 incubation period. Monitoring cleavage of caspases by western blot analysis revealed that CIK cells without or with BV6 increased activation of caspases-3, -8, and -9 and cleavage of Bid to tBid. The truncated form of Bid (i.e., tBid) links the extrinsic apoptotic pathway and the intrinsic (mitochondrial) apoptotic pathway by triggering mitochondrial outer membrane permeabilization (MOMP).
However, BV6 both sensitized target cells for killing and had an inhibitory effect on effector cells. For assessment of BV6 effects on CIK cells, which may limit applicability of combination therapy, CIK cells were treated with increasing doses of BV6. Remarkably, not only BV6 treatment, but also the presence of target cells alone, induced apoptosis in CIK cells. Accordingly, Nishimura et al. (55) demonstrated high percentages of early apoptotic cells in mice transplanted with CIK cells alone, suggesting that CIK cells per se demonstrated limited life span and increased susceptibility to apoptosis. Our results confirmed high expression levels of active caspase-3 fragments as a sign of activated apoptosis pathways in CIK cells being in contact with tumor cells. Interestingly, increased caspase-3-like activity has previously been detected in non-apoptotic T cells demonstrating that caspase-3-activation does not necessarily lead to apoptosis (56) . Alternatively, CIK cells may undergo apoptosis during killing of tumor cells. Therefore the www.frontiersin.org relevance of caspase activation in CIK cells remains to be explored in future studies.
Altogether, our results showed that CIK cells were affected by BV6. However, despite being affected as well by BV6, adding CIK cells to co-cultures of BV6 and tumor cells significantly increased cytotoxicity against malignant cells compared to BV6 or CIK cell treatment alone. This may allow clinical applicability of combination therapy. However, further pre-clinical analyzes will be mandatory to optimize BV6 dosage and time interval between BV6 and CIK cell applications. Furthermore, serial CIK cell infusions may be considered in this context. Accordingly, effects of SMAC mimetic BV6 on conventional immune cells were analyzed by Muller-Sienerth et al. (57) . Considering the role of NFκB transcription factors in the immune system, they found that BV6-induced apoptotic and necrotic cell death in monocytes while T cells, dendritic cells, and macrophages were largely protected against BV6-induced cell death.
Of note, our results also demonstrated BV6-mediated sensitization of non-malignant cells like PMNCs toward CIK cellmediated killing, which may increase risk for graft versus host disease or graft failure and therefore may complicate the development of tumor therapeutic concepts based on CIK cell infusions combined with BV6 cancer therapies. However, absolute cytotoxicity values against PMNCs ranged between 16.0 ± 0.40% and 22.0 ± 0.4% while specific lysis of malignant cells reached a maximum of 62.3 ± 2.0% and 76.0 ± 3.5% without or after addition of 2.5 µMol BV6, respectively. This difference may hint toward a more selective killing of malignant cells while almost sparing non-malignant cells. Moreover our clinical data showed that even in the haploidentical stem cell transplantation setting, alloreactive potential of CIK cells remained low. Here, serial infusions of 1 × 10 8 CD3 + CD56 − CIK cells/kg recipient body weight generated from the original haploidentical stem cell donor for treatment of relapse post-transplant were well tolerated and no signs of acute graft versus host disease occurred (GvHD) (58) .
Moreover, due to the diverse character of CIK cells it remained unclear, which effector cell population was supported most by the administration of SMAC mimetic BV6. Hence, more specific cell therapy approaches such as CAR T cells, TCR-transduced T cells, or specific T cell clones would have been more applicable in combination with BV6. Further analyses may also address the question, if the effector cell inhibition refers to BV6 per se, or SMAC mimetics in general. Another IAP, i.e., Birinapant (TL32711) a bivalent SMAC mimetic that recently afforded synergistic cytotoxicity of chemotherapeutic agents and displayed significant antitumor activity at well-tolerated doses in murine xenograft models could also be analyzed in context of cell therapy-based combination strategies (35) .
In conclusion, CIK cell-mediated cytotoxicity by target cell pretreatment with the IAP BV6 was limited as CIK cells were also affected by BV6. However, cytotoxic effects were dose-and target cell-dependent and increased especially when BV6 and CIK cells were used sequentially compared to BV6 or CIK cell treatment alone. Altogether, the combination strategy of cellular therapies and IAP may represent a treatment approach for resistant tumor targets, which still warrants further investigation in pre-clinical in vitro and in vivo models.
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